Core Insights - CalciMedica Inc. has appointed Dr. Alan Glicklich to its Board of Directors, effective January 15, 2025, bringing over 20 years of biotechnology experience [1][2] Company Overview - CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases [4] - The company's lead product candidate, Auxora™, has shown positive clinical results in multiple trials, targeting conditions such as acute pancreatitis and acute kidney injury [4] Leadership and Expertise - Dr. Glicklich's previous roles include Chief Medical Officer at Nuvig Therapeutics, Chinook Therapeutics, and Bird Rock Bio, where he led various clinical development initiatives [2][3] - His expertise includes designing successful Phase 3 studies and managing clinical operations across multiple therapeutic areas [2][3] Clinical Development - CalciMedica is progressing Auxora towards a Phase 3 trial in acute pancreatitis and is awaiting data from the KOURAGE trial in acute kidney injury [2] - The company has completed a Phase 2 trial in patients with COVID pneumonia and is conducting ongoing trials in pediatric patients with asparaginase-induced pancreatic toxicity [4]
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors